IMC GP75

Drug Profile

IMC GP75

Alternative Names: gp75 DNA vaccine; GP75 MAb - Eli Lilly; IMC-GP75; Melanoma vaccine - ImClone Systems

Latest Information Update: 01 May 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Nov 2008 Eli Lilly acquires ImClone Systems
  • 25 Jul 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 28 Oct 2004 No Development Reported - Preclinical for hTRPx3 for melanoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top